The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Annual General Meeting

23 Nov 2016 11:30

RNS Number : 9559P
Diurnal Group PLC
23 November 2016
 

23 November 2016

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Results of Annual General Meeting

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed. All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

 

 

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolutions (requires 50% majority)

1. To receive and adopt the Company's audited annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

2. To reappoint Peter Allen as a director.

39,347,209

100%

0

0%

0

3. To reappoint Ian Ardill as a director.

39,347,209

100%

0

0%

0

4. To reappoint John Goddard as a director.

39,347,209

100%

0

0%

0

5. To reappoint Alan Raymond as a director.

39,347,209

100%

0

0%

0

6. To reappoint Richard Ross as a director.

39,347,209

100%

0

0%

0

7. To reappoint Martin Whitaker as a director.

39,347,209

100%

0

0%

0

8. To reappoint Sam Williams as a director.

39,347,209

100%

0

0%

0

9. To receive and approve the directors' remuneration report contained within the annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

10. To reappoint KPMG LLP as auditors of the Company.

39,347,209

100%

0

0%

0

11. To authorise the directors to determine the remuneration of the auditors.

39,347,209

100%

0

0%

0

12. To authorise the directors to allot shares.

39,347,209

100%

0

0%

0

Special Resolutions (requires 75% majority)

13. To authorise the directors to disapply pre-emption rights.

39,347,209

100%

0

0%

0

14. To authorise the Company to make market purchases.

39,347,209

100%

0

0%

0

 

 

* A vote withheld is not a vote in law and is not counted in the calculation of the votes for or against a resolution; the percentage of votes cast therefore excludes withheld votes.

 

On 23 November 2016 there were 52,210,759 Diurnal Group plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

 

The full text of each resolution passed at the Annual General Meeting held earlier today, is set out in the Notice of Annual General Meeting, included in the 2016 Annual Report, which is available on the Company's website www.diurnal.co.uk.

 

 

Please further information, please visit www.diurnal.co.uk or contact:

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+ 44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBJBBTMBBTBPF
Date   Source Headline
7th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
7th Sep 20229:58 amRNSForm 8.5 (EPT/RI)
7th Sep 20229:23 amRNSMole Valley Asset Management Ltd-Form 8.3 Diurnal
6th Sep 20221:36 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
6th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
6th Sep 20229:04 amRNSForm 8.3 - [DIURNAL GROUP PLC]
5th Sep 20223:16 pmRNSForm 8.3 - Diurnal Group Plc
5th Sep 20221:36 pmRNSForm 8 (OPD) (Diurnal Group)
5th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
2nd Sep 20224:28 pmRNSForm 8 (OPD) (Neurocrine Biosciences, Inc.)
2nd Sep 20222:55 pmRNSForm 8.3 - Diurnal Group plc
2nd Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
2nd Sep 20228:58 amRNSForm 8.5 (EPT/RI)
1st Sep 20223:12 pmRNSForm 8.3 - Diurnal Group plc
1st Sep 20221:20 pmRNSForm 8.3 - Diurnal Group Plc
1st Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
1st Sep 202210:04 amRNSForm 8.5 (EPT/RI)
1st Sep 20229:38 amRNSForm 8.3 - [DIURNAL GROUP PLC]
1st Sep 20227:00 amRNSPostponement of R&D Day and Notice of Results
31st Aug 20223:20 pmRNSForm 8.3 - Diurnal Group plc
31st Aug 20222:03 pmRNSForm 8.3 - Diurnal Group PLC
31st Aug 202212:53 pmRNSForm 8.3 DIURNAL GROUP PLC
31st Aug 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
31st Aug 202211:56 amRNSForm 8.5 (EPT/RI) - Diurnal Group PLC
31st Aug 202211:55 amRNSForm 8.3 - Diurnal Group plc
31st Aug 202211:46 amGNWForm 8.3 - [Diurnal Group plc - 30 08 2022 - Opening Declaration] - (HHL)
31st Aug 20229:08 amRNSForm 8.3 - Diurnal Group PLC
30th Aug 202212:55 pmRNSForm 8.3 - DIURNAL GROUP PLC
30th Aug 202212:32 pmEQSForm 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc
30th Aug 20227:00 amRNSRECOMMENDED CASH ACQUISITION
26th Jul 20227:00 amRNSTrading Update
15th Jul 202212:04 pmRNSDirector Dealings
30th Jun 20221:29 pmRNSBlock Listing Six Monthly Return
7th Jun 20221:00 pmRNSDiurnal to present research at ENDO 2022
1st Jun 20227:00 amRNSFirst patient dosed in pivotal Phase 3 trial
23rd May 20228:41 amRNSCorrection: Presentation at ECE
23rd May 20227:00 amRNSPresentation at European Congress of Endocrinology
9th May 202212:49 pmRNSDirector Dealings
29th Apr 20223:37 pmRNSTotal Voting Rights
28th Apr 20227:00 amRNSDiurnal to present at Investor Evening
25th Apr 20227:00 amRNSDistribution agreement signed with EffRx
20th Apr 20227:00 amRNSDistribution agreement signed with Er-Kim
4th Apr 20227:00 amRNSDirectorate Change and Management Updates
1st Apr 20227:00 amRNSTotal Voting Rights
30th Mar 20227:00 amRNSDistribution agreement with Vector Pharma
22nd Mar 20224:35 pmRNSPrice Monitoring Extension
22nd Mar 20222:06 pmRNSSecond Price Monitoring Extn
22nd Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSInterim Results
9th Mar 20227:00 amRNSInterim Results Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.